AstraZeneca ADR To Join The Nasdaq-100 Index Starting Feb. 22, 2022

2/10/22 5:01:28 PM ET

$AZN

$NDAQ

$XLNX

Biotechnology: Pharmaceutical Preparations

Health Care

Investment Bankers/Brokers/Service

Finance

Get the next $AZN alert in real time by email

Nasdaq (NASDAQ:NDAQ) today announced that AstraZeneca PLC – ADR (NASDAQ:AZN), will become a component of the NASDAQ-100 Index® (NASDAQ:NDX) and the NASDAQ-100 Equal Weighted Index (NASDAQ:NDXE) prior to market open on Tuesday, February 22, 2022. AstraZeneca PLC – ADR will replace Xilinx, Inc. (NASDAQ:XLNX) in the NASDAQ-100 Index® and the NASDAQ-100 Equal Weighted Index.

For more information about the company, go to https://www.astrazeneca.com.

Get the next $AZN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AZN
$NDAQ
$XLNX

Company	Date	Price Target	Rating	Analyst
AstraZeneca PLC $AZN	11/20/2024		Sell → Neutral	UBS
AstraZeneca PLC $AZN	11/6/2024		Sell → Hold	Deutsche Bank
Nasdaq Inc. $NDAQ	10/14/2024	$82.00	Mkt Perform → Outperform	Raymond James
Nasdaq Inc. $NDAQ	9/27/2024	$88.00	Outperform	RBC Capital Mkts
Nasdaq Inc. $NDAQ	9/26/2024	$83.00	Hold	TD Cowen
AstraZeneca PLC $AZN	9/13/2024		Hold → Sell	Deutsche Bank
Nasdaq Inc. $NDAQ	9/9/2024	$78.00 → $80.00	Outperform	Oppenheimer
Nasdaq Inc. $NDAQ	9/4/2024	$53.00 → $90.00	Underperform → Buy	BofA Securities

More analyst ratings

$AZN
$NDAQ
$XLNX
Financials

Live finance-specific insights

AstraZeneca's 9M and Q3 2024 results
Upgrade to full year 2024 guidance underpinned by strong underlying growth momentum AstraZeneca: Revenue and EPS summary 9M 2024 % Change Q3 2024 % Change $m Actual CER1 $m Actual CER - Product Sales 37,576 16 19 12,947 18 20 - Alliance Revenue 1,498 49 50 559 48 50 - Collaboration Revenue 108 (66) (66) 59 (39) (40) Total Revenue 39,182 16 19 13,565 18 21 Reported EPS $3.57 11 21
11/12/24 7:00:00 AM ET
$AZN
Biotechnology: Pharmaceutical Preparations
Health Care
Nasdaq Announces Quarterly Dividend of $0.24 Per Share
NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Nasdaq, Inc. (NASDAQ:NDAQ) has declared a regular quarterly dividend of $0.24 per share on the company's outstanding common stock. The dividend is payable on December 20, 2024 to shareholders of record at the close of business on December 6, 2024. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by the Board of Directors. About Nasdaq Nasdaq (NASDAQ:NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital marke
10/24/24 7:01:00 AM ET
$NDAQ
Investment Bankers/Brokers/Service
Finance
Nasdaq Reports Third Quarter 2024 Results; Fourth Consecutive Quarter of Double-Digit Solutions Revenue Growth
NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (NASDAQ:NDAQ) today reported financial results for the third quarter of 2024. Third quarter 2024 net revenue1 was $1.1 billion, or $1.2 billion on a non-GAAP basis2, an increase of 22% over the third quarter of 2023, up 10% on a pro forma3 basis. This included Solutions4 revenue increasing 26%, or 10% on a pro forma basis.Annualized Recurring Revenue (ARR)5 of $2.7 billion increased 31% over the third quarter of 2023, up 8% on a pro forma basis.Financial Technology revenue of $371 million increased 56% over the third quarter of 2023, up 10% on a pro forma basis.Index revenue of $182 million increased 26%, with $62 bill
10/24/24 7:00:00 AM ET
$NDAQ
Investment Bankers/Brokers/Service
Finance

AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US
US ACT on Health Equity contributions support AstraZeneca's long-term ambition in health equity and total more than $15 million to date AstraZeneca today pledged $3.5 million to nonprofit organizations across the US as part of Accelerate Change Together (ACT) on Health Equity, an initiative to improve access, affordability and outcomes for patients in urban, suburban and rural communities. This brings the total contributions from the program to more than $15 million to date. Now in its fourth year, ACT on Health Equity will fund 53 nonprofit programs which aim to improve access to healthcare, address housing and nutrition as social determinants of health, advance culturally competent ch
11/20/24 7:30:00 AM ET
$AZN
Biotechnology: Pharmaceutical Preparations
Health Care
GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
MENLO PARK, Calif., Nov. 18, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first patient has been tested for eligibility with the investigational GRAIL Non-Small Cell Lung Cancer (NSCLC) ctDNA Assay in the global TROPION-Lung12 Phase 3 study evaluating adjuvant treatment regimens in patients with Stage I adenocarcinoma NSCLC. The study is sponsored by AstraZeneca (NASDAQ:AZN) in collaboration with Daiichi Sankyo (TSE: 4568). The study, which is being conducted under a
11/18/24 4:01:00 PM ET
$AZN
$GRAL
Biotechnology: Pharmaceutical Preparations
Health Care
Medical Specialities
AstraZeneca's 9M and Q3 2024 results
Upgrade to full year 2024 guidance underpinned by strong underlying growth momentum AstraZeneca: Revenue and EPS summary 9M 2024 % Change Q3 2024 % Change $m Actual CER1 $m Actual CER - Product Sales 37,576 16 19 12,947 18 20 - Alliance Revenue 1,498 49 50 559 48 50 - Collaboration Revenue 108 (66) (66) 59 (39) (40) Total Revenue 39,182 16 19 13,565 18 21 Reported EPS $3.57 11 21
11/12/24 7:00:00 AM ET
$AZN
Biotechnology: Pharmaceutical Preparations
Health Care

AppLovin Corporation to Join the Nasdaq-100 Index® Beginning November 18, 2024
NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that AppLovin Corporation (NASDAQ:APP), will become a component of the Nasdaq-100 Index® (NASDAQ:NDX) and the Nasdaq-100 Equal Weighted™ Index (NASDAQ:NDXE) prior to market open on Monday, November 18, 2024. AppLovin Corporation will replace Dollar Tree, Inc. (NASDAQ:DLTR) in the Nasdaq-100 Index® and the Nasdaq-100 Equal Weighted™ Index. Dollar Tree, Inc. will also be removed from the Nasdaq-100 Ex-Tech Sector™ Index (NASDAQ:NDXX), the Nasdaq-100 ESG™ Index (NASDAQ:NDXESG), the Nasdaq-100 Sustainable ESG Select™ Index (NASDAQ:NDXSES) , the Nasdaq-100 ex Top 30™ Index (NASDAQ:NDX), and the Nasdaq-100 ex T
11/8/24 8:00:00 PM ET
$APP
$DLTR
$NDAQ
Computer Software: Programming Data Processing
Technology
Department/Specialty Retail Stores
Consumer Discretionary
Nasdaq to Join the American Bankers Association's Partner Network as a Premier Partner
As a Premier Partner, ABA members will have the opportunity to benefit from Nasdaq's advanced solutions for innovation, collaboration and enhanced efficiency including Nasdaq Verafin® and Nasdaq Governance Solutions Nasdaq announced today that it will join the American Bankers Association (ABA) Partner Network as a Premier Partner. Through the newly established partnership, Nasdaq will provide ABA members with an extensive library of expert resources and software tools to help them tackle the most complex problems faced by the financial industry across risk management, anti-financial crime, as well as supporting better workflow and efficiency in how they manage governance and board activi
10/28/24 8:00:00 AM ET
$NDAQ
Investment Bankers/Brokers/Service
Finance
Nasdaq Announces New Leadership and Structure for Financial Crime Management Technology
Appoints 13-year Nasdaq Verafin Veteran, Stephanie Champion, as New Head of Nasdaq Verafin Nasdaq Chief Strategy Officer, Jeremy Skule, to Take on Expanded Role as Executive Chair of Nasdaq's Financial Crime Management Technology Business NEW YORK and ST. JOHN'S, Newfoundland, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ), today announced a new leadership structure including leadership appointment for its Financial Crime Management Technology business, designed to support the business' strong momentum and continuing its growth trajectory. Effective today, Brendan Brothers, EVP, Head of Financial Crime Management Technology, and Verafin Co-Founder will step ba
9/6/24 7:00:49 AM ET
$NDAQ
Investment Bankers/Brokers/Service
Finance

AstraZeneca ADR To Join The Nasdaq-100 Index Starting Feb. 22, 2022

Chat with this insight

Recent Analyst Ratings for $AZN$NDAQ$XLNX

$AZN$NDAQ$XLNX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Zollar Alfred W bought $203,970 worth of shares (2,542 units at $80.24), increasing direct ownership by 5% to 49,293 units (SEC Form 4)

Torgeby Johan bought $705,880 worth of shares (14,000 units at $50.42), increasing direct ownership by 165% to 22,466 units (SEC Form 4)

$AZN$NDAQ$XLNX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Nasdaq Inc.

SEC Form SC 13G filed by Nasdaq Inc.

Amendment: SEC Form SC 13G/A filed by Nasdaq Inc.

$AZN$NDAQ$XLNX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

AstraZeneca upgraded by UBS

AstraZeneca upgraded by Deutsche Bank

NASDAQ upgraded by Raymond James with a new price target

$AZN$NDAQ$XLNX Financials

Live finance-specific insights

AstraZeneca's 9M and Q3 2024 results

Nasdaq Announces Quarterly Dividend of $0.24 Per Share

Nasdaq Reports Third Quarter 2024 Results; Fourth Consecutive Quarter of Double-Digit Solutions Revenue Growth

$AZN$NDAQ$XLNX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Executive Vice President Skule Jeremy sold $950,906 worth of shares (12,075 units at $78.75), decreasing direct ownership by 11% to 102,505 units (SEC Form 4)

Director Zollar Alfred W bought $203,970 worth of shares (2,542 units at $80.24), increasing direct ownership by 5% to 49,293 units (SEC Form 4)

Executive Vice President Peterson Bradley J sold $940,636 worth of shares (11,820 units at $79.58), decreasing direct ownership by 8% to 131,010 units (SEC Form 4)

$AZN$NDAQ$XLNX SEC Filings

SEC Form 6-K filed by AstraZeneca PLC

SEC Form 6-K filed by AstraZeneca PLC

SEC Form 6-K filed by AstraZeneca PLC

$AZN$NDAQ$XLNX Market Insights

Live Market Insights

AstraZeneca shares are trading lower after the company reported Q2 earnings.

Nasdaq Q2 Earnings: Revenue Surge, Financial Tech and Index Segments Show Strong Growth

Nasdaq shares are trading higher after the company reported better-than-expected Q2 financial results.

$AZN$NDAQ$XLNX Press Releases

Fastest customizable press release news feed in the world

$AZN$NDAQ$XLNX Leadership Updates

Live Leadership Updates

AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US

GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study

AstraZeneca's 9M and Q3 2024 results

AppLovin Corporation to Join the Nasdaq-100 Index® Beginning November 18, 2024

Nasdaq to Join the American Bankers Association's Partner Network as a Premier Partner

Nasdaq Announces New Leadership and Structure for Financial Crime Management Technology

Recent Analyst Ratings for
$AZN
$NDAQ
$XLNX

$AZN
$NDAQ
$XLNX
Insider Purchases

$AZN
$NDAQ
$XLNX
Large Ownership Changes

$AZN
$NDAQ
$XLNX
Analyst Ratings

$AZN
$NDAQ
$XLNX
Financials

$AZN
$NDAQ
$XLNX
Insider Trading

$AZN
$NDAQ
$XLNX
SEC Filings

$AZN
$NDAQ
$XLNX
Market Insights

$AZN
$NDAQ
$XLNX
Press Releases

$AZN
$NDAQ
$XLNX
Leadership Updates